Butanoic acid, 4-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]amino]- manufacturers
- Pomalidomide-C3-COOH
-
- $0.00 / 50mg
-
2024-04-02
- CAS:2225940-47-4
- Min. Order: 50mg
- Purity: >95.00%
- Supply Ability: 50mg
|
| | Butanoic acid, 4-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]amino]- Basic information |
| Product Name: | Butanoic acid, 4-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]amino]- | | Synonyms: | Butanoic acid, 4-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]amino]-;DUN 40474;Pomalidomide-C3-COOH;4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)butanoic acid;Butanoic acid, 4[[2(2,6dioxo3piperidinyl)2,3dihydro1,3dioxo1Hisoindol4yl]amino],Butanoic acid, 4 [[2 (2,6 dioxo 3 piperidinyl) 2,3 dihydro 1,3 dioxo 1H isoindol 4 yl]amino;Thalidomide-NH-C3-COOH;4-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)butanoic acid, Crosslinker–E3 Ligase ligand conjugate, Protein degrader building block for PROTAC? research, Template for synthesis of targeted protein degrader;Thalidomide-4-NH-C3-COOH | | CAS: | 2225940-47-4 | | MF: | C17H17N3O6 | | MW: | 359.33 | | EINECS: | | | Product Categories: | | | Mol File: | 2225940-47-4.mol | ![Butanoic acid, 4-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]amino]- Structure](CAS/20200611/GIF/2225940-47-4.gif) |
| | Butanoic acid, 4-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]amino]- Chemical Properties |
| | Butanoic acid, 4-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]amino]- Usage And Synthesis |
| Uses | Protein degrader builiding block Pomalidomide-C3-CO2H enables the synthesis of molecules for targeted protein degradation and PROTAC (proteolysis-targeting chimeras) technology. This conjugate contains a Cereblon (CRBN)-recruiting ligand and an alkyl-chain crosslinker with pendant carboxylic acid for reactivity with an amine on the target ligand. Because even slight alterations in ligands and crosslinkers can affect ternary complex formation between the target, E3 ligase, and PROTAC, many analogs are prepared to screen for optimal target degradation. When used with other protein degrader building blocks with a pendant carboxyl group, parallel synthesis can be used to more quickly generate PROTAC libraries that feature variation in crosslinker length, composition, and E3 ligase ligand. | | storage | Store at -20°C |
| | Butanoic acid, 4-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]amino]- Preparation Products And Raw materials |
|